Solution structures of cyclic melanocortin agonists and antagonists by NMR.
about
Design, synthesis and biological evaluation of ligands selective for the melanocortin-3 receptorInteractions of human melanocortin 4 receptor with nonpeptide and peptide agonistsStructure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 receptorThe Melanocortin Receptor System: A Target for Multiple Degenerative DiseasesMultiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.Design of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the challengeConformational study on cyclic melanocortin ligands and new insight into their binding mode at the MC4 receptor.Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain.Synthesis, biophysical, and pharmacological evaluation of the melanocortin agonist AST3-88: modifications of peptide backbone at Trp 7 position lead to a potent, selective, and stable ligand of the melanocortin 4 receptor (MC4R).Solid-phase peptide head-to-side chain cyclodimerization: discovery of C(2)-symmetric cyclic lactam hybrid α-melanocyte-stimulating hormone (MSH)/agouti-signaling protein (ASIP) analogues with potent activities at the human melanocortin receptorsOrganic chemistry and biology: chemical biology through the eyes of collaboration.1,4-disubstituted-[1,2,3]triazolyl-containing analogues of MT-II: design, synthesis, conformational analysis, and biological activity.Structure-activity studies of new melanocortin peptides containing an aromatic amino acid at the N-terminal position.Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities.Interactions of the melanocortin-4 receptor with the peptide agonist NDP-MSH.Cyclic lactam hybrid α-MSH/Agouti-related protein (AGRP) analogues with nanomolar range binding affinities at the human melanocortin receptorsDesign, synthesis, and biological evaluation of new cyclic melanotropin peptide analogues selective for the human melanocortin-4 receptorDesign of cyclic and other templates for potent and selective peptide alpha-MSH analogues.Effects of macrocycle size and rigidity on melanocortin receptor-1 and -5 selectivity in cyclic lactam alpha-melanocyte-stimulating hormone analogs.Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffoldAn unusual conformation of γ-melanocyte-stimulating hormone analogues leads to a selective human melanocortin 1 receptor antagonist for targeting melanoma cells.Design and microwave-assisted synthesis of novel macrocyclic peptides active at melanocortin receptors: discovery of potent and selective hMC5R receptor antagonists.Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 receptor.Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors.Beta-turn secondary structure and melanocortin ligands.Solution structures and molecular interactions of selective melanocortin receptor antagonists.Structural Insights into Selective Ligand-Receptor Interactions Leading to Receptor Inactivation Utilizing Selective Melanocortin 3 Receptor Antagonists.
P2860
Q24649952-C90C9110-E265-4284-B549-4FC7F61F1D3CQ24653618-6D2F38B6-A7C7-4FEB-ADA0-FDCA604CD15CQ24653947-1161A67B-F69D-46D5-A641-8EE7DDB3F7EFQ28273671-33E5E887-4A0B-43EE-9A3C-0D3A75BAA440Q33585575-722B57F0-65D5-4973-9F21-D2DA5C8A200FQ33786376-0CBD400C-89A2-48E7-8D19-AF9611E7654CQ33926210-19CBCC58-7E21-4DF3-A143-58999E8C7BE5Q34049320-A9A234E8-CA9A-4815-9AA3-161B5403DF55Q34343356-51B56A2A-E9DA-4442-8B3A-74107739CAC5Q34583185-C81EEFBB-7382-44FC-9542-F2FC21BF3CC5Q34583191-35BC8CAD-C61F-481C-8DC6-2084B33CFA9DQ34631536-E5E95E9E-7FED-4DBA-B117-D6636A6BCC47Q34700718-1A330402-D94B-40DB-9250-D5A30473CE9EQ34703179-C39171A0-7F15-4AE7-AC1D-1C69E39F1A06Q35004622-3C682A48-E778-4632-8E2A-284495D60893Q35551884-DC01868A-9661-4D7A-9FB4-D6F36CCC3C5EQ35574655-B801B200-155D-4A03-B605-6B51E3DDCF1CQ35676897-C1FEF180-DC9C-4F15-8BCD-F4CC9AA89792Q35750424-1E53C235-F782-40C7-B699-C29678C82BD7Q36741936-050F5AD1-548C-49DE-A26D-57920F82C35DQ36809168-91DFCFB9-A82A-48C8-82E9-D2C814A8A83FQ37372714-21166568-CEC2-47D4-8CBD-3EFBB7D72A91Q37417029-DE91473F-D51A-4418-8F6C-85B1A9330DBAQ40239862-2D008C11-3966-4687-8908-F31A15D073DEQ41957100-48966395-8D4B-4FCA-97E6-D5083BECA9BDQ42791882-E74124AF-24A2-439B-BB55-D87C6A350F66Q45063479-E7B6F265-35F5-44D0-B103-F3F7E38F7CF0
P2860
Solution structures of cyclic melanocortin agonists and antagonists by NMR.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Solution structures of cyclic melanocortin agonists and antagonists by NMR.
@ast
Solution structures of cyclic melanocortin agonists and antagonists by NMR.
@en
type
label
Solution structures of cyclic melanocortin agonists and antagonists by NMR.
@ast
Solution structures of cyclic melanocortin agonists and antagonists by NMR.
@en
prefLabel
Solution structures of cyclic melanocortin agonists and antagonists by NMR.
@ast
Solution structures of cyclic melanocortin agonists and antagonists by NMR.
@en
P2093
P2860
P356
P1433
P1476
Solution structures of cyclic melanocortin agonists and antagonists by NMR.
@en
P2093
Dev B Trivedi
Guoxia Han
Jinfa Ying
Katalin E Kövér
Malcolm J Kavarana
Victor J Hruby
P2860
P304
P356
10.1002/BIP.10596
P577
2003-01-01T00:00:00Z